Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR AMPLIFICATION
(
ENST00000275493.7 )
EGFR AMPLIFICATION ( ENST00000275493.7 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. This study reports that the Src-AKT pathway contributes to acquired resistance to third generation EGFR TKIs. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3015
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/190
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Osimertinib,Rociletinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 28202511
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Osimertinib | Resitance or Non-Reponse | true |
| Rociletinib | Resitance or Non-Reponse | true |